Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Apr 27,2022
Medicilon was selected into the Biomedicine Index
Shanghai Medicilon Inc. (Medicilon) was selected as a sample of the Biomedicine Index and became one of the top 5 heavyweight stocks.
More
Medicilon was selected into the Biomedicine Index
Apr 27,2022
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
On April 20th, the 2021 Drug Innovation Award sponsored by Securities Times, Medicilon was awarded the "Top Ten Drug Innovation Service Organizations of the Year" in the 2021 Drug Innovation Award.
More
Medicilon was awarded the Top Ten Drug Innovation Service Organizations of the Year in the 2021 Drug Innovation Award
Apr 27,2022
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
On March 9, the "Hi Liquid Workplace" 2021 China Annual Best Employer Awards Ceremony of the Yangtze River Delta region ended successfully online. Shanghai Medicilon Inc. (Medicilon) won the "Top 50 China Best Employer Award 2021."
More
Medicilon won the "Top 50 China Best Employer Award 2021" on March 9
Apr 27,2022
Medicilon was selected as a constituent stocks of the STAR 50 Index
On February 25, the Shanghai Stock Exchange announced that they decided to adjust the sample of the STAR 50 Index, which will take effect after the market closes on March 11, 2022.
More
Medicilon was selected as a constituent stocks of the STAR 50 Index
Apr 19,2022
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Medicilon is deeply aware of its responsibilities toemployees, pharmaceutical companies and scientific research institutions, and even for the entire biopharmaceutical industry chain as an integrated prclinial R&D facility.
More
Lockdown But Not Stop - Medicilon Researchers Continue to Fight
Apr 19,2022
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Shanghai Medicilon Inc. announced the appointment of Dr. Christopher Stewart, DABT as the Senior Scientific Advisor of Medicilon.
More
Medicilon Appoints Dr. Christopher Stewart, DABT as Senior Scientific Advisor
Mar 14,2022
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Shanghai Medicilon Inc. (Medicilon) provided GLP-compliant toxicology DRF tests and application materials for the research and development of YY001, which accelerating the project to get into Phase 1 clinical trials.
More
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Mar 02,2022
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
On February 22, Shanghai Medicilon Inc (Medicilon)'s partner Imbioray (Hangzhou) Biomedicine Co., Ltd. (Imbioray) announced the completion of RMB 230 million Round A financing.
More
Focus on Universal CAR-NK Cell Therapy! Medicilon's Partner Imbioray Completes 230 million Round A Financing
Feb 28,2022
Medicilon Won Praise and Awards From Many Partners
Leading Tac Pharma's PROTAC drug project is a first-in-class research and development project that challenges anti-tumor and autoimmune diseases. In the cooperation with Medicilon, the Medicilon's DMPK team actively communicated with Leading Tac which helped customers solve a series of research and development problems such as large molecular weight, ensuring the completion of the project.
More
Medicilon Won Praise and Awards From Many Partners
Feb 18,2022
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Zhenrong Guo as the Executive Vice President of VCMC(APIs + Preparations).
More
Medicilon Appoints Dr. Zhenrong Guo as Executive Vice President of VCMC
Feb 17,2022
World's First Inhaled Nanobody Drug LQ036
In the development process of the world's first inhaled nanobody drug for the treatment of moderate and severe asthma, Medicilon assists LQ036 to complete the quality research services of inhaled preparations.
More
World's First Inhaled Nanobody Drug LQ036
Jan 27,2022
Happy Chinese New Year!
Happy Chinese New Year!
More
Happy Chinese New Year!
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->